Drug Regulatory Authority of Pakistan (DRAP) has approved another Chinese Coronavirus vaccine for the phase-III clinical trial that will be held at the University of Health Sciences (UHS) Lahore.
Known as ZF2001, the three-dose Coronavirus vaccine has been developed by Anhui Zhifei Longcom, a Chinese biopharmaceutical company, in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences.
According to details, UHS has already made necessary arrangements for the final stage clinical trial that will start next week.
The safety and efficacy of ZF2001 will be determined through a randomized, double-blind, placebo-controlled trial involving 10,000 volunteers of 18 years of age and above.
The study’s participants will be administered the three doses of ZF2001 in three months after which the clinical trial will enter the follow-up stage.
All volunteers will be required to visit the trial site 7 times during the three months for which they will be paid Rs. 16,000 for food and travel expense.
So far, DRAP has approved four Coronavirus vaccines for use in the country, which include China’s Sinopharm and CansinoBio, UK’s AstraZeneca/Oxford, and Russia’s Sputnik V.